Grade 4 Epistaxis in a Woman with Metastatic Breast Cancer Treated with Bevacizumab: A Case Report

Yanagihara, Keiko; Takei, Hiroyuki; Iida, S.; Yamashita, Koji; Kurita, Tomoyuki; Iwamoto, Miki; Saegusa, Hideto; Uchida, Eiji

doi:10.1272/jnms.81.333

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epistaxis and alveolar hemorrhage have been reported to be caused by bevacizumab [29,30]. In most patients, bleeding is light, with severe bleeding only occurring in 1.37% of patients.…”

Section: Discussionmentioning

confidence: 99%

“…Bevacizumab-induced bleeding is due to damage to vascular endothelial cells due to inhibition of angiogenesis and abnormal coagulation profile due to depletion of VEGF in platelets, which promotes the formation of thrombi [ 28 ]. Epistaxis and alveolar hemorrhage have been reported to be caused by bevacizumab [ 29 , 30 ]. In most patients, bleeding is light, with severe bleeding only occurring in 1.37% of patients.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports

Rehman¹,

Ullah²,

Nagarajan³

et al. 2022

Cureus

View full text Add to dashboard Cite

Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that binds to and makes all of the VEGF isoforms inactive, and thus prevents angiogenesis, development, and the spread of the tumor. The most reported side effects after administering bevacizumab include bleeding, high blood pressure, heart failure, proteinuria, thrombosis, and gastrointestinal perforation. Pneumothorax has rarely been reported as a complication of bevacizumab, but with an unclear mechanism. This article aims to explore the occurrence of pneumothorax as a side effect after using bevacizumab through a systematic review of current case reports published on the topic. A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Directory of Open Access through the utilization of appropriate keywords, and case reports were selected based on predefined inclusion and exclusion criteria. Our results encompass five case reports that were further evaluated for demographic, clinical, and treatment parameters. This systematic review concludes that pneumothorax can occur after bevacizumab-containing chemotherapy although this side effect is relatively rare. Awareness regarding this possible side effect can assist clinicians during their practice in considering pneumothorax as a possible differential diagnosis when encountering patients presenting with pulmonary symptoms after starting bevacizumab-containing chemotherapy; hence, timely diagnosis and treatment can save a life.

show abstract

“…Epistaxis and alveolar hemorrhage have been reported to be caused by bevacizumab [29,30]. In most patients, bleeding is light, with severe bleeding only occurring in 1.37% of patients.…”

Section: Discussionmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports

Rehman¹,

Ullah²,

Nagarajan³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Epistaxis and alveolar hemorrhage have been reported to be caused by BV (8,9). Bleeding is light in most patients, and severe bleeding occurs in 1.37% of the patients.…”

Section: Discussionmentioning

confidence: 99%

“…As mechanisms underlying BV-induced bleeding, vascular endothelial damage due to inhibition of angiogenesis and abnormal coagulation due to VEGF depletion in platelets, which causes the formation of thrombi, have been reported ( 7 ). Epistaxis and alveolar hemorrhage have been reported to be caused by BV ( 8 , 9 ). Bleeding is light in most patients, and severe bleeding occurs in 1.37% of the patients.…”

Section: Discussionmentioning

confidence: 99%

A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab

et al. 2016

View full text Add to dashboard Cite

The patient was a 57-year-old man who was diagnosed with multiple lung metastases of sigmoid colon cancer. The patient developed progressive disease after 8 courses of bevacizumab + capecitabine and oxaliplatin therapy, therefore, bevacizumab + irinotecan, leucovorin, and 5-fluorouracil therapy was started. During the fifth course, he experienced pain on the left side of his chest. On computed tomography, bleeding from the pulmonary metastatic lesions was suspected. Two days later, a pneumothorax was detected. Although several cases of pneumothorax induced by bevacizumab have been reported, this case is the first documentation that bevacizumab caused a rupture of the lung metastatic lesion, leading to a pneumothorax.

show abstract

Bevacizumab

2014

Reactions Weekly

View full text Add to dashboard Cite

Grade 4 Epistaxis in a Woman with Metastatic Breast Cancer Treated with Bevacizumab: A Case Report

Cited by 3 publications

References 13 publications

Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports

Pneumothorax as a Complication of Bevacizumab-Containing Chemotherapy: A Systematic Review of Case Reports

A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab

Bevacizumab

Contact Info

Product

Resources

About